Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.32 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29148559 | 0.88 | CA12 (0.37) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL2362714 | 0.84 | KDM4E (0.47) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL4220982 | 0.84 | SMN1; SMN2 (0.46) | KDM4EALDH1A1SMN1; SMN2NPC1HPGD | |
| SCHEMBL2512844 | 0.82 | ALDH1A1 (0.47) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL21604132 | 0.80 | PKM (0.35) | KDM4EALDH1A1SMN1; SMN2NPC1PKM | |
| SCHEMBL21597813 | 0.78 | PKM (0.41) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL19556332 | 0.78 | CA12 (0.40) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL25348892 | 0.77 | PKM (0.40) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL2516485 | 0.76 | CA12 (0.44) | CA12CA1CA2CA9KDM4E | |
| SCHEMBL17473324 | 0.76 | CA12 (0.41) | CA12CA1CA2CA9KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2024-06-25 | — | — | US | disclosed |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | UCB Biopharma SRL (BE) | 2022-10-20 | — | — | US | disclosed |
| EP-3810606-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2021-04-28 | — | — | EP | disclosed |
| CN-112566910-A | Thiophene derivatives for the treatment of IgE induced diseases | UCB生物制药有限责任公司 | 2021-03-26 | — | — | CN | disclosed |
| WO-2019243550-A1 | THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE | UCB Biopharma SRL (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| EP-2352723-B1 | PESTICIDAL N-ARYL- OR N-HETEROARYL PYRAZOLE CARBOXAMIDE COMPOUNDS | BAYER IP GMBH (DE) | 2016-11-23 | — | — | EP | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-20150099766-A1 | Novel halogen-substituted compounds | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-04-09 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-8946234-B2 | Halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2015-02-03 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20110301181-A1 | halogen-substituted compounds | BAYER CROPSCIENCE AG (DE) | 2011-12-08 | — | — | US | disclosed |
| EP-2352723-A2 | HALOGEN-SUBSTITUTED COMPOUNDS USED AS PESTICIDES | Bayer CropScience AG (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010051926-A2 | NEW HALOGEN-SUBSTITUTED BONDS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301181-A1 | halogen-substituted compounds | L3MBTL4, QSOX1, L3MBTL3 | CA12 4272/4885CA1 2723/4885CA2 3243/4885 |
| US-20220332709-A1 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | CA12 1917/4885CA1 2121/4885CA2 1144/4885 |
| US-12018021-B2 | Thiophene derivatives for the treatment of disorders caused by IgE | TSLP, CYSLTR1, CYSLTR2 | CA12 1917/4885CA1 2121/4885CA2 1144/4885 |
| US-20150099766-A1 | Novel halogen-substituted compounds | L3MBTL4, PRDX4, PRDX1 | CA12 4138/4885CA1 2596/4885CA2 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.